Are you Dr. Paschke?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 53 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
34th & Civic Center Blvd
Children's Hospital Of Philadelphia
Philadelphia, PA 19104Phone+1 215-590-1000Fax+1 215-590-2204
Summary
- Dr. Amanda Paschke, MD is a pediatric infectious disease specialist in Philadelphia, Pennsylvania. She is currently licensed to practice medicine in Pennsylvania.
Education & Training
Children's Hospital of PhiladelphiaFellowship, Pediatric Infectious Diseases, 2007 - 2010- Children's Hospital of PhiladelphiaResidency, Pediatrics, 2004 - 2007
State University of New York Downstate Medical Center College of MedicineClass of 2004
Certifications & Licensure
PA State Medical License 2004 - 2024- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Infectious Diseases
Publications & Presentations
PubMed
- 16 citationsComparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilast...Keith S Kaye, Helen W. Boucher, Michelle L Brown, Angela Aggrey, Ireen Khan
Antimicrobial Agents and Chemotherapy. 2020-04-21 - 128 citationsPhase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal InfectionChristopher Lucasti, Liviu Vasile, Dorel Sandesc, Donatas Venskutonis, Patrick McLeroth
Antimicrobial Agents and Chemotherapy. 2016-09-23 - 68 citationsPrevious Antimicrobial Exposure Is Associated With Drug-Resistant Urinary Tract Infections in ChildrenAmanda A. Paschke, Theoklis E. Zaoutis, Patrick H. Conway, Dawei Xie, Ron Keren
Pediatrics. 2010-04-01
Press Mentions
Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM MicrobeJune 20th, 2016
